New Dual-Target antibody enters human trials for advanced cancers
NCT ID NCT05357651
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard treatments. The main goal is to check safety and tolerability, while also looking at how the drug moves through the body and whether it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LB1410 (a bispecific antibody that targets two immune checkpoints, PD-1 and TIM-3)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 100 participants, so safety and effectiveness are not yet proven. There is a risk of immune-related side effects, and the drug may not work for all tumor types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••